繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 肿瘤 >> 新药推荐 >> 雷利米得胶囊REVLIMID(来那度胺 LENALIDOMIDE)

雷利米得胶囊REVLIMID(来那度胺 LENALIDOMIDE)

2013-04-27 11:54:39  作者:新特药房  来源:互联网  浏览次数:297  文字大小:【】【】【
简介: 药品信息:以下信息来自互联网,本站不负责信息的准确性。温馨提示:因抗肿瘤药品比较特殊,建议患者购买任何抗癌药品须由专业肿瘤科医生处方后取药,医嘱用药,才能安全、有效。REVLIMID® (lenalid ...

REVLIMID - lenalidomide capsule 
Celgene Corporation
来那度胺(Lenalidomide/Revlimid) fda批准revlimid用于治疗骨髓增生异常综合征
美国食品药品管理局(fda)批准了美国细胞基因公司的来那度胺(lenalidomide/revlimid)。 revlimid为口服制剂evlimid(lenalidomide)是由celgene公司研发的用于治疗致死性血液疾病以及癌症的药物。该品是用于治疗孕吐曾引起数以千计的婴儿出生缺陷沙利度胺(thalidomide)的加强版,具有抗癌潜力。与沙利度胺相比,其不良反应更少,研究证明其不会引起婴儿出生缺陷。
2005年9月,fda肿瘤药物顾问委员会建议以revlimid用于治疗输液依赖型贫血症。输液依赖型贫血症是由于5q染色体异常相关的骨髓增生异常综合征所引起的。10月,欧洲药品管理局接受了revlimid的上市申请。同时,该品在欧洲获得了治疗骨髓增生异常综合征的罕用药物和治疗多发性骨髓瘤的罕用药物的地位。
celgene公司计划在2006年第一季度分别向美国fda和欧洲药品管理局提交本品用于治疗复发型难治性多发性骨髓瘤的补充新药申请。
revlimid对细胞内多种生物途径都有影响。目前celgene公司仍在进行本品的血液学和肿瘤学治疗作用评估,包括多发性骨髓瘤、骨髓增生异常综合征、慢性淋巴细胞白血病以及实体瘤。骨髓增生异常综合征是一种恶性血液疾病,全球大约有30万患者。当骨髓中的血细胞始终处于不成熟阶段从而不能履行其必要功能时,骨髓增生异常综合征就会发生。骨髓中充满了这些不成熟细胞,抑制了正常细胞的发展。骨髓增生异常综合征患者必须经常依靠输血来抵抗贫血、疲劳等症状,直到发展成为威胁生命的铁超负荷或者铁中毒。该疾病的治疗迫切需要一种治本的方法而不仅仅是控制症状。超过一半的骨髓增生异常综合征患者诊断出细胞染色体变异,包括一个以上染色体的部分或完全缺失。骨髓增生异常综合征中最常见的细胞染色体异常出现在5、7和20号染色体的q缺失。另一比较普遍的变异是8号染色体的额外复制。5q染色体的缺失在骨髓增生异常综合征患者中的比例可达20%~30%。
revlimid为口服制剂,且毒性较低,该品获批后将成为骨髓增生异常综合征患者的治疗选择之一。

REVLIMID® (lenalidomide)
5 mg, 10 mg, 15 mg and 25 mg capsules

WARNINGS:

  1. POTENTIAL FOR HUMAN BIRTH DEFECTS
  2. HEMATOLOGIC TOXICITY (NEUTROPENIA AND THROMBOCYTOPENIA)
  3. DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM

POTENTIAL FOR HUMAN BIRTH DEFECTS

WARNING: POTENTIAL FOR HUMAN BIRTH DEFECTS

LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY. FEMALES SHOULD BE ADVISED TO AVOID PREGNANCY WHILE TAKING REVLIMID® (lenalidomide).

Special Prescribing Requirements

BECAUSE OF THIS POTENTIAL TOXICITY AND TO AVOID FETAL EXPOSURE TO REVLIMID® (lenalidomide), REVLIMID® (lenalidomide) IS ONLY AVAILABLE UNDER A SPECIAL RESTRICTED DISTRIBUTION PROGRAM. THIS PROGRAM IS CALLED "RevAssist®". UNDER THIS PROGRAM, ONLY PRESCRIBERS AND PHARMACISTS REGISTERED WITH THE PROGRAM CAN PRESCRIBE AND DISPENSE THE PRODUCT. IN ADDITION, REVLIMID® (lenalidomide) MUST ONLY BE DISPENSED TO PATIENTS WHO ARE REGISTERED AND MEET ALL THE CONDITIONS OF THE RevAssist® PROGRAM.

PLEASE SEE THE FOLLOWING INFORMATION FOR PRESCRIBERS, FEMALE PATIENTS, AND MALE PATIENTS ABOUT THIS RESTRICTED DISTRIBUTION PROGRAM.

RevAssist® PROGRAM DESCRIPTION

Prescribers

REVLIMID® (lenalidomide) can be prescribed only by licensed prescribers who are registered in the RevAssist® program and understand the potential risk of teratogenicity if lenalidomide is used during pregnancy.

Effective contraception must be used by female patients of childbearing potential for at least 4 weeks before beginning REVLIMID® (lenalidomide) therapy, during REVLIMID® (lenalidomide) therapy, during dose interruptions and for 4 weeks following discontinuation of REVLIMID® (lenalidomide) therapy. Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy or because the patient has been postmenopausal naturally for at least 24 consecutive months. Two reliable forms of contraception must be used simultaneously unless continuous abstinence from heterosexual sexual contact is the chosen method. Females of childbearing potential should be referred to a qualified provider of contraceptive methods, if needed. Sexually mature females who have not undergone a hysterectomy, have not had a bilateral oophorectomy or who have not been postmenopausal naturally for at least 24 consecutive months (i.e., who have had menses at some time in the preceding 24 consecutive months) are considered to be females of childbearing potential.

Before prescribing REVLIMID® (lenalidomide), females of childbearing potential should have 2 negative pregnancy tests (sensitivity of at least 50 mIU/mL). The first test should be performed within 10–14 days, and the second test within 24 hours prior to prescribing REVLIMID® (lenalidomide). A prescription for REVLIMID® (lenalidomide) for a female of childbearing potential must not be issued by the prescriber until negative pregnancy tests have been verified by the prescriber.

Male Patients: It is not known whether lenalidomide is present in the semen of patients receiving the drug. Therefore, males receiving REVLIMID® (lenalidomide) must always use a latex condom during any sexual contact with females of childbearing potential even if they have undergone a successful vasectomy.

Once treatment has started and during dose interruptions, pregnancy testing for females of childbearing potential should occur weekly during the first 4 weeks of use, then pregnancy testing should be repeated every 4 weeks in females with regular menstrual cycles. If menstrual cycles are irregular, the pregnancy testing should occur every 2 weeks. Pregnancy testing and counseling should be performed if a patient misses her period or if there is any abnormality in her pregnancy test or in her menstrual bleeding. REVLIMID® (lenalidomide) treatment must be discontinued during this evaluation.

Pregnancy test results should be verified by the prescriber and the pharmacist prior to dispensing any prescription.

If pregnancy does occur during REVLIMID® (lenalidomide) treatment, REVLIMID® (lenalidomide) must be discontinued immediately.

Any suspected fetal exposure to REVLIMID® (lenalidomide) should be reported to the FDA via the MedWatch number at 1-800-FDA-1088 and also to Celgene Corporation at 1-888-423-5436. The patient should be referred to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling.

Female Patients

REVLIMID® (lenalidomide) should be used in females of childbearing potential only when the patient MEETS ALL OF THE FOLLOWING CONDITIONS (i.e., she is unable to become pregnant while on lenalidomide therapy):

  • she understands and can reliably carry out instructions.
  • she is capable of complying with the mandatory contraceptive measures, pregnancy testing, patient registration, and patient survey as described in the RevAssist® program.
  • she has received and understands both oral and written warnings of the potential risks of taking lenalidomide during pregnancy and of exposing a fetus to the drug.
  • she has received both oral and written warnings of the risk of possible contraception failure and of the need to use two reliable forms of contraception simultaneously, unless continuous abstinence from heterosexual sexual contact is the chosen method. Sexually mature females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months (i.e., who have had menses at some time in the preceding 24 consecutive months), or had a bilateral oophorectomy are considered to be females of childbearing potential.
  • she acknowledges, in writing, her understanding of these warnings and of the need for using two reliable methods of contraception for 4 weeks prior to beginning lenalidomide therapy, during lenalidomide therapy, during dose interruptions and for 4 weeks after discontinuation of lenalidomide therapy.
  • she has had two negative pregnancy tests with a sensitivity of at least 50 mIU/mL, within 10-14 days and 24 hours prior to beginning therapy.
  • if the patient is between 12 and 18 years of age, her parent or legal guardian must have read the educational materials and agreed to ensure compliance with the above.

Male Patients

REVLIMID® (lenalidomide) should be used in sexually active males when the PATIENT MEETS ALL OF THE FOLLOWING CONDITIONS:

  • he understands and can reliably carry out instructions.
  • he is capable of complying with the mandatory contraceptive measures that are appropriate for men, patient registration, and patient survey as described in the RevAssist® program.
  • he has received and understands both oral and written warnings of the potential risks of taking lenalidomide and exposing a fetus to the drug.
  • he has received both oral and written warnings of the risk of possible contraception failure and that it is unknown whether lenalidomide is present in semen. He has been instructed that he must always use a latex condom during any sexual contact with females of childbearing potential, even if he has undergone a successful vasectomy.
  • he acknowledges, in writing, his understanding of these warnings and of the need to use a latex condom during any sexual contact with females of childbearing potential, even if he has undergone a successful vasectomy. Females of childbearing potential are considered to be sexually mature females who have not undergone a hysterectomy, have not had a bilateral oophorectomy or who have not been postmenopausal for at least 24 consecutive months (i.e., who have had menses at any time in the preceding 24 consecutive months).
  • if the patient is between 12 and 18 years of age, his parent or legal guardian must have read the educational materials and agreed to ensure compliance with the above.

HEMATOLOGIC TOXICITY (NEUTROPENIA AND THROMBOCYTOPENIA)

This drug is associated with significant neutropenia and thrombocytopenia. Eighty percent of patients with del 5q myelodysplastic syndromes had to have a dose delay/reduction during the major study. Thirty-four percent of patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. Patients on therapy for del 5q myelodysplastic syndromes should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Patients may require dose interruption and/or reduction. Patients may require use of blood product support and/or growth factors. (See DOSAGE AND ADMINISTRATION)

DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM

This drug has demonstrated a significantly increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients with multiple myeloma who were treated with REVLIMID® (lenalidomide) combination therapy. Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. It is not known whether prophylactic anticoagulation or antiplatelet therapy prescribed in conjunction with REVLIMID® (lenalidomide) may lessen the potential for venous thromboembolic events. The decision to take prophylactic measures should be done carefully after an assessment of an individual patient’s underlying risk factors.

You can get the information about REVLIMID® (lenalidomide) and the RevAssist® program on the internet at www.REVLIMID.com or by calling the manufacturer’s toll free number 1-888-423-5436.

DESCRIPTION

REVLIMID® (lenalidomide), a thalidomide analogue, is an immunomodulatory agent with antiangiogenic and antineoplastic properties. The chemical name is 3-(4-amino-1-oxo 1,3-dihydro-2H-isoindol-2-yl) piperidine-2,6-dione and it has the following chemical structure:

3-(4-amino-1-oxo 1,3-dihydro-2H-isoindol-2-yl) piperidine-2,6-dione

The empirical formula for lenalidomide is C13H13N3O3, and the gram molecular weight is 259.3.

Lenalidomide is an off-white to pale-yellow solid powder. It is soluble in organic solvent/water mixtures, and buffered aqueous solvents. Lenalidomide is more soluble in organic solvents and low pH solutions. Solubility was significantly lower in less acidic buffers, ranging from about 0.4 to 0.5 mg/ml. Lenalidomide has an asymmetric carbon atom and can exist as the optically active forms S(-) and R(+), and is produced as a racemic mixture with a net optical rotation of zero.

REVLIMID® (lenalidomide) is available in 5 mg, 10 mg, 15 mg and 25 mg capsules for oral administration. Each capsule contains lenalidomide as the active ingredient and the following inactive ingredients: lactose anhydrous, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The 5 mg and 25 mg capsule shell contains gelatin, titanium dioxide and black ink. The 10 mg capsule shell contains gelatin, FD&C blue #2, yellow iron oxide, titanium dioxide and black ink. The 15 mg capsule shell contains gelatin, FD&C blue #2, titanium dioxide and black ink.

CLINICAL PHARMACOLOGY

Mechanism of Action

The mechanism of action of lenalidomide remains to be fully characterized. Lenalidomide possesses antineoplastic, immunomodulatory and antiangiogenic properties. Lenalidomide inhibited the secretion of pro-inflammatory cytokines and increased the secretion of antiinflammatory cytokines from peripheral blood mononuclear cells. Lenalidomide inhibited cell proliferation with varying effectiveness (IC50s) in some but not all cell lines. Of cell lines tested, lenalidomide was effective in inhibiting growth of Namalwa cells (a human B cell lymphoma cell line with a deletion of one chromosome 5) but was much less effective in inhibiting growth of KG-1 cells (human myeloblastic cell line, also with a deletion of one chromosome 5) and other cell lines without chromosome 5 deletions. Lenalidomide inhibited the growth of multiple myeloma cells from patients, as well as MM.1S cells (a human multiple myeloma cell line), by inducing cell cycle arrest and apoptosis.

Lenalidomide inhibited the expression of cyclooxygenase-2 (COX-2) but not COX-1 in vitro.

Pharmacokinetics and Drug Metabolism

Absorption:

Lenalidomide, in healthy volunteers, is rapidly absorbed following oral administration with maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. Co‑administration with food does not alter the extent of absorption (AUC) but does reduce the maximal plasma concentration (Cmax) by 36%. The pharmacokinetic disposition of lenalidomide is linear. Cmax and AUC increase proportionately with increases in dose. Multiple dosing at the recommended dose-regimen does not result in drug accumulation.

Pharmacokinetic sampling in myelodysplastic syndromes (MDS) patients was not performed. In multiple myeloma patients maximum plasma concentrations occurred between 0.5 and 4.0 hours post-dose both on Days 1 and 28. AUC and Cmax values increase proportionally with dose following single and multiple doses. Exposure (AUC) in multiple myeloma patients is 57% higher than in healthy male volunteers.

Pharmacokinetic Parameters

Distribution:

In vitro (14C)-lenalidomide binding to plasma proteins is approximately 30%.

Metabolism and Excretion:

The metabolic profile of lenalidomide in humans has not been studied. In healthy volunteers, approximately two-thirds of lenalidomide is eliminated unchanged through urinary excretion. The process exceeds the glomerular filtration rate and therefore is partially or entirely active. Half‑life of elimination is approximately 3 hours.

Special Populations:

Patients with Renal Insufficiency: The pharmacokinetics of lenalidomide were studied in patients with renal impairment due to nonmalignant conditions. In this study, 5 patients with mild renal function impairment (creatinine clearance 57-74 mL/min), 6 patients with moderate renal function impairment (creatinine clearance 33-46 mL/min), 6 patients with severe renal function impairment (creatinine clearance 17-29 mL/min), and 6 patients with end stage renal disease requiring dialysis were administered a single oral 25-mg dose of REVLIMID® (lenalidomide). As a control group comparator, 7 healthy subjects of similar age with normal renal function (creatinine clearance 83-145 mL/min) were also administered a single oral 25-mg dose of REVLIMID® (lenalidomide). As creatinine clearance decreased from mild to severe impairment, half-life increased and drug clearance decreased linearly. Patients with moderate and severe renal impairment had a 3-fold increase in half-life and a 66% to 75% decrease in drug clearance compared to healthy subjects. Patients on hemodialysis (n=6) given a single, 25-mg dose of lenalidomide had an approximate 4.5-fold increase in half-life and an 80% decrease in drug clearance compared to healthy subjects. Approximately 40% of the administered dose was removed from the body during a single dialysis session.

Adjustment of the starting dose of REVLIMID® (lenalidomide) is recommended in patients with moderate or severe (CLcr < 60 mL/min) renal impairment and in patients on dialysis. See DOSAGE AND ADMINISTRATION.

In multiple myeloma patients, those patients with mild renal impairment had an AUC 56% greater than those with normal renal function.

Patients with Hepatic Disease: The pharmacokinetics of lenalidomide in patients with hepatic impairment have not been studied.

Age: The effects of age on the pharmacokinetics of lenalidomide have not been studied.

Pediatric: No pharmacokinetic data are available in patients below the age of 18 years.

Gender: The effects of gender on the pharmacokinetics of lenalidomide have not been studied.

Race: Pharmacokinetic differences due to race have not been studied.

CLINICAL STUDIES

Myelodysplastic Syndromes (MDS) with a Deletion 5q Cytogenetic Abnormality

The efficacy and safety of REVLIMID® (lenalidomide) were evaluated in patients with transfusion dependent anemia in Low- or Intermediate-1- risk MDS with a 5q (q31-33) cytogenetic abnormality in isolation or with additional cytogenetic abnormalities, at a dose of 10 mg once daily or 10 mg once daily for 21 days every 28 days in an open-label, single-arm, multi-center study. The major study was not designed nor powered to prospectively compare the efficacy of the 2 dosing regimens. Sequential dose reductions to 5 mg daily and 5 mg every other day, as well as dose delays, were allowed for toxicity.

This major study enrolled 148 patients who had RBC transfusion dependent anemia. RBC-transfusion dependence was defined as having received ≥ 2 units of RBCs within 8 weeks prior to study treatment. The study enrolled patients with absolute neutrophil counts (ANC) ≥ 500/mm3, platelet counts ≥ 50,000/mm3, serum creatinine ≤ 2.5 mg/dL, serum SGOT/AST or SGPT/ALT ≤ 3.0 x upper limit of normal (ULN), and serum direct bilirubin ≤ 2.0 mg/dL. Granulocyte colony-stimulating factor was permitted for patients who developed neutropenia or fever in association with neutropenia. Baseline patient and disease-related characteristics are summarized in Table 1.

Table 1: Baseline Demographic and Disease-Related Characteristics
[a] IPSS Risk Category: Low (combined score = 0), Intermediate-1 (combined score = 0.5 to 1.0), Intermediate-2 (combined score = 1.5 to 2.0), High (combined score ≥ 2.5); Combined score = (Marrow blast score + Karyotype score + Cytopenia score)
[b] French-American-British (FAB) classification of MDS.
Overall
(N=148)
Age (years)

  Median

71.0
  Min, Max 37.0, 95.0
Gender n (%)
  Male 51 (34.5)
  Female 97 (65.5)
Race n (%)
  White 143 (96.6)
  Other 5 (3.4)
Duration of MDS (years)
  Median 2.5
  Min, Max 0.1, 20.7
Del 5 (q31-33) Cytogenetic Abnormality n (%)
  Yes 148 (100.0)
  Other cytogenetic abnormalities 37 (25.2)
IPSS Score [a] n (%)
  Low (0) 55 (37.2)
  Intermediate-1 (0.5-1.0) 65 (43.9)
  Intermediate-2 (1.5-2.0) 6 (4.1)
  High (≥2.5) 2 (1.4)
  Missing 20 (13.5)
FAB Classification [b] from central review n (%)
  RA 77 (52.0)
  RARS 16 (10.8)
  RAEB 30 (20.3)
  CMML 3 (2.0)

The frequency of RBC-transfusion independence was assessed using criteria modified from the International Working Group (IWG) response criteria for MDS. RBC transfusion independence was defined as the absence of any RBC transfusion during any consecutive “rolling” 56 days (8 weeks) during the treatment period.

Transfusion independence was seen in 99/148 (67%) patients (95% CI [59, 74]). The median duration from the date when RBC transfusion independence was first declared (i.e., the last day of the 56-day RBC transfusion-free period) to the date when an additional transfusion was received after the 56-day transfusion-free period among the 99 responders was 44 weeks (range of 0 to >67 weeks).

Ninety percent of patients who achieved a transfusion benefit did so by completion of three months in the study.

RBC-transfusion independence rates were unaffected by age or gender.

The dose of REVLIMID® (lenalidomide) was reduced or interrupted at least once due to an adverse event in 118 (79.7%) of the 148 patients; the median time to the first dose reduction or interruption was 21 days (mean, 35.1 days; range, 2-253 days), and the median duration of the first dose interruption was 22 days (mean, 28.5 days; range, 2-265 days). A second dose reduction or interruption due to adverse events was required in 50 (33.8%) of the 148 patients. The median interval between the first and second dose reduction or interruption was 51 days (mean, 59.7 days; range, 15-205 days) and the median duration of the second dose interruption was 21 days (mean, 26 days; range, 2-148 days).

Granulocyte colony-stimulating factors were permitted for patients who developed neutropenia or fever in association with neutropenia.

Multiple Myeloma

Two randomized studies (Studies 1 and 2) were conducted to evaluate the efficacy and safety of REVLIMID® (lenalidomide). These multicenter, multinational, double-blind, placebo-controlled studies compared REVLIMID® (lenalidomide) plus oral pulse high-dose dexamethasone therapy to dexamethasone therapy alone, in patients with multiple myeloma who had received at least one prior treatment.

In both studies, patients in the REVLIMID® (lenalidomide)/dexamethasone group took 25 mg of REVLIMID® (lenalidomide) orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28‑day cycle. Patients in the placebo/dexamethasone group took 1 placebo capsule on Days 1 to 28 of each 28‑day cycle. Patients in both treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28‑day cycle for the first 4 cycles of therapy.

The dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 of each 28‑day cycle after the first 4 cycles of therapy. In both studies, treatment was to continue until disease progression.

In both studies, dose adjustments were allowed based on clinical and laboratory findings. Sequential dose reductions to 15 mg daily, 10 mg daily and 5 mg daily were allowed for toxicity. (See DOSAGE AND ADMINISTRATION)

Table 2 summarizes the baseline patient and disease characteristics in the two studies. In both studies, baseline demographic and disease-related characteristics were comparable between the REVLIMID® (lenalidomide)/dexamethasone and placebo/dexamethasone groups.

Table 2: Baseline Demographic and Disease-Related Characteristics - Studies 1 and 2
Study 1 Study 2
REVLIMID/Dex
N=170
Placebo/Dex
N=171
REVLIMID/Dex
N=176
Placebo/Dex
N=175
Patient Characteristics
Age (years)
                 Median 64 62 63 64
                 Min,Max 36,86 37, 85 33, 84 40, 82
Sex
                 Male 102 (60%) 101 (59%) 104 (59%) 103 (59%)
                 Female 68 (40%) 70 (41%) 72 (41%) 72 (41%)
Race/Ethnicity
                 White 134 (79%) 143 (84%) 172 (98%) 175 (100%)
                 Other 36 (21%) 28 (16%) 4 (2%) 0 (0%)
ECOG Performance Status 0-1 151 (89%) 163 (95%) 150 (85%) 144 (82%)
Disease Characteristics
Baseline Multiple Myeloma Stage (Durie-Salmon)
                 I 2% 2% 6% 5%
                 II 31% 31% 28% 33%
                 III 67% 67% 65% 63%
Baseline Creatinine (mg/dL)
                 Median 1.0 1.0 0.9 0.9
                 Min,Max 0.4, 2.6 0.5, 2.4 0.3, 2.3 0.5, 2.3
B2-microglobulin (mg/L)
                 Median 3.7 3.3 3.4 3.3
                 Min,Max 1.1, 45 1.3, 15.2 1.0, 14.4 1.3, 25.3
Number of Prior Therapies
No. of Prior Antimyeloma Therapies
                 1 38% 37% 32% 33%
                 ≥2 62% 63% 68% 67%
Types of Prior Therapies
Stem Cell Transplantation 60% 60% 56% 54%
Thalidomide 42% 46% 30% 38%
Dexamethasone 80% 70% 66% 69%
Bortezomib 11% 12% 5% 4%
Melphalan 34% 31% 56% 52%
Doxorubicin 55% 52% 56% 57%

The primary efficacy endpoint in both studies was time to progression (TTP). TTP was defined as the time from randomization to the first occurrence of progressive disease or death due to progressive disease.

Preplanned interim analyses of both studies showed that the combination of REVLIMID® (lenalidomide)/dexamethasone was significantly superior to dexamethasone alone for TTP. The studies were unblinded to allow patients in the placebo/dexamethasone group to receive treatment with the REVLIMID® (lenalidomide)/dexamethasone combination.

Table 3 summarizes TTP and response rates based on the best response assessments for Studies 1 and 2.


Table 3: Summary of Efficacy Analysis — Studies 1 and 2
1 NE, Not estimable due to short follow-up.
2 Hazard Ratio of Revlimid/Dexamethasone to Placebo/Dexamethasone
3 The p-value is based on a one-tailed unstratified log rank test.
Study 1 Study 2
REVLIMID/Dex
N=170
Placebo/Dex
N=171
REVLIMID/Dex
N=176
Placebo/Dex
N=175
TTP
Censored
n (%)
115 (68) 61 (36) 133 (76) 78 (45)
Median TTP in
weeks
[95% CI]

37.1
[28, NE1]

19.9
[16, 22]
NE1
20
[19.9, 21.6]

Hazard Ratio2
[95% CI]
0.356 [0.257, 0.494] 0.392 [0.274, 0.562]
Log-rank Test
p-value 3
<0.0001 <0.0001
Response
Complete
Response (CR)
n (%)
14 (8) 1 (1) 14 (8) 1 (1)
Partial
Response
(RR/PR) n (%)
76 (44) 27 (16) 76 (43) 33 (19)
Overall
Response
n (%)
90 (53) 28 (16) 90 (51) 34 (19)
p-value <0.0001 <0.0001
Odds Ratio
[95% CI]
5.5 [3.3, 9.1] 4.3 [2.7, 7.0]

Figures 1 and 2 depict the Kaplan-Meier estimates of TTP in Studies 1 and 2, respectively.

Figure 1: Kaplan-Meier Estimate of Time to Progression - Study 1

The median duration of Study 1 follow-up was 20.1 weeks.

Figure 2: Kaplan-Meier Estimate of Time to Progression - Study 2

The median duration of Study 2 follow-up was 22.3 weeks.

INDICATIONS AND USAGE

REVLIMID® (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.

CONTRAINDICATIONS

Pregnancy Category X: (See BOXED WARNINGS)

Due to its structural similarities to thalidomide, a known human teratogen, and data from an embryofetal development study showing treatment with lenalidomide produced malformations in the offspring of female monkeys who received the drug during pregnancy, lenalidomide is contraindicated in pregnant women and women capable of becoming pregnant. (See BOXED WARNINGS.) When there is no alternative, females of childbearing potential may be treated with lenalidomide provided adequate precautions are taken to avoid pregnancy. Females must commit either to abstain continuously from heterosexual sexual intercourse or to use two methods of reliable birth control, including at least one highly effective method (e.g., IUD, hormonal contraception, tubal ligation, or partner’s vasectomy) and one additional effective method (e.g., latex condom, diaphragm, or cervical cap), beginning 4 weeks prior to initiating treatment with REVLIMID® (lenalidomide), during therapy with REVLIMID® (lenalidomide), during therapy delay, and continuing for 4 weeks following discontinuation of REVLIMID® (lenalidomide) therapy. If hormonal or IUD contraception is medically contraindicated, two other effective or highly effective methods may be used.

Females of childbearing potential being treated with REVLIMID® (lenalidomide) should have pregnancy testing (sensitivity of at least 50 mIU/mL). The first test should be performed within 10-14 days and the second test within 24 hours prior to beginning REVLIMID® (lenalidomide) therapy and then weekly during the first month of REVLIMID® (lenalidomide), then monthly thereafter in women with regular menstrual cycles or every 2 weeks in women with irregular menstrual cycles. Pregnancy testing and counseling should be performed if a patient misses her period or if there is any abnormality in menstrual bleeding. If pregnancy occurs, REVLIMID® (lenalidomide) must be immediately discontinued. Under these conditions, the patient should be referred to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling.

REVLIMID® (lenalidomide) is contraindicated in any patients who have demonstrated hypersensitivity to the drug or its components.

WARNINGS

Pregnancy Category X: (See BOXED WARNINGS and CONTRAINDICATIONS)

REVLIMID® (lenalidomide) is an analogue of thalidomide. Thalidomide is a known human teratogen that causes life-threatening human birth defects. An embryofetal development study in non-human primates indicates that lenalidomide produced malformations in the offspring of female monkeys who received the drug during pregnancy, similar to birth defects observed in humans following exposure to thalidomide during pregnancy. The teratogenic effect of lenalidomide in humans cannot be ruled out. REVLIMID® (lenalidomide) may cause fetal harm when administered to a pregnant female. Females of childbearing potential should be advised to avoid pregnancy while on REVLIMID® (lenalidomide). Two effective contraceptive methods should be used during therapy, during therapy interruptions and for at least 4 weeks after completing therapy.

There are no adequate and well-controlled studies in pregnant females.

Because of this potential toxicity and to avoid fetal exposure to REVLIMID® (lenalidomide), REVLIMID® (lenalidomide) is only available under a special restricted distribution program. This program is called RevAssist®.

Lenalidomide has been shown to have an embryocidal effect in rabbits at a dose of 50 mg/kg (approximately 120 times the human dose of 10 mg based on body surface area).

An embryo-fetal development study in rats revealed no teratogenic effects at the highest dose of 500 mg/kg (approximately 600 times the human dose of 10 mg based on body surface area). At 100, 300 or 500 mg/kg/day there was minimal maternal toxicity that included slight, transient, reduction in mean body weight gain and food intake. However this animal model may not adequately address the full spectrum of the potential embryo-fetal developmental effects of lenalidomide.

A pre- and post-natal development study in rats revealed few adverse effects on the offspring of female rats treated with lenalidomide at doses up to 500 mg/kg (approximately 600 times the human dose of 10 mg based on body surface area). The male offspring exhibited slightly delayed sexual maturation and the female offspring had slightly lower body weight gains during gestation when bred to male offspring.

The structural similarity of lenalidomide to thalidomide, a known human teratogen, as well as malformations seen in the offspring of female monkeys administered lenalidomide during pregnancy, suggests a potential risk to the developing fetus.

HEMATOLOGIC TOXICITY (NEUTROPENIA AND THROMBOCYTOPENIA):

This drug is associated with significant neutropenia and thrombocytopenia.

Eighty percent of patients with del 5q MDS had to have a dose delay or reduction during the major study for the indication. Thirty-four percent of patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. In the 48% of patients who developed Grade 3 or 4 neutropenia, the median time to onset was 42 days (range, 14-411 days), and the median time to documented recovery was 17 days (range, 2-170 days). In the 54% of patients who developed Grade 3 or 4 thrombocytopenia, the median time to onset was 28 days (range, 8-290 days), and the median time to documented recovery was 22 days (range, 5-224 days). Patients on therapy for del 5q myelodysplastic syndromes should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Patients may require dose interruption and/or reduction. Patients may require use of blood product support and/or growth factors. (See DOSAGE AND ADMINISTRATION)

In the pooled multiple myeloma studies Grade 3 and 4 hematologic toxicities were more frequent in patients treated with the combination of REVLIMID® (lenalidomide) and dexamethasone than in patients treated with dexamethasone alone. (See ADVERSE REACTIONS: Table 7.) Patients on therapy should have their complete blood counts monitored every 2 weeks for the first 12 weeks and then monthly thereafter. Patients may require dose interruption and/or dose reduction. (See DOSAGE AND ADMINISTRATION)

DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM:

This drug has demonstrated a significantly increased risk of DVT and PE in patients with multiple myeloma who were treated with REVLIMID® (lenalidomide) combination therapy. Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. It is not known whether prophylactic anticoagulation or antiplatelet therapy prescribed in conjunction with REVLIMID® (lenalidomide) may lessen the potential for venous thromboembolic events. The decision to take prophylactic measures should be done carefully after an assessment of an individual patient’s underlying risk factors. (See ADVERSE REACTIONS: Table 7)

PRECAUTIONS

Angioedema, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Angioedema and serious dermatologic reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported. These events can be fatal. Patients with a prior history of Grade 4 rash associated with thalidomide treatment should not receive REVLIMID® (lenalidomide). REVLIMID® (lenalidomide) interruption or discontinuation should be considered for Grade 2-3 skin rash. REVLIMID® (lenalidomide) must be discontinued for angioedema, Grade 4 rash, exfoliative or bullous rash, or if SJS or TEN is suspected, and should not be resumed following discontinuation for these reactions.

Tumor Lysis Syndrome

Lenalidomide has antineoplastic activity and therefore the complications of tumor lysis syndrome may occur. The patients at risk of tumor lysis syndrome are those with high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.

Information for Patients

Patients should be counseled on lenalidomide’s potential risk of teratogenicity due to its structural similarity to thalidomide and data from an embryofetal development study showing treatment with lenalidomide produced malformations in the offspring of female monkeys who received the drug during pregnancy. Patients may only acquire a prescription for REVLIMID® (lenalidomide) therapy through a controlled distribution program (RevAssist®) through contracted pharmacies. Female patients of childbearing potential will be educated and counseled on the requirements of the RevAssist® program and the precautions to be taken to preclude fetal exposure to REVLIMID® (lenalidomide). Patients should become familiar with the REVLIMID® (lenalidomide) RevAssist® educational materials and Patient Medication Guide, and direct any questions to their physician or pharmacist prior to starting REVLIMID® (lenalidomide) therapy.

Laboratory Tests

The MDS clinical study enrolled patients with absolute neutrophil counts (ANC) ≥ 500/mm3, platelet counts ≥ 50,000/mm3, serum creatinine ≤ 2.5 mg/dL, serum SGOT/AST or SGPT/ALT ≤ 3.0 x upper limit of normal (ULN), and serum direct bilirubin ≤ 2.0 mg/dL. A complete blood cell count (CBC), including white blood cell count with differential, platelet count, hemoglobin, and hematocrit should be performed weekly for the first 8 weeks of REVLIMID® (lenalidomide) treatment and monthly thereafter to monitor for cytopenias.

The multiple myeloma Studies 1 and 2 enrolled patients with absolute neutrophil counts (ANC) ≥ 1000/mm3, platelet counts ≥ 75,000/mm3, serum creatinine ≤ 2.5 mg/dL, serum SGOT/AST or SGPT/ALT ≤ 3.0 x upper limit of normal (ULN), and serum direct bilirubin ≤ 2.0 mg/dL. A CBC should be performed every two weeks for the first three months and at least monthly thereafter to monitor for cytopenias.

Drug Interactions

Results from human in vitro metabolism studies and nonclinical studies show that REVLIMID® (lenalidomide) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that lenalidomide is not likely to cause or be subject to P450-based metabolic drug interactions in man.

Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of R- and S-warfarin. Co-administration of single 25-mg dose warfarin had no effect on the pharmacokinetics of total lenalidomide. Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant lenalidomide administration.

When digoxin was co-administered with lenalidomide the digoxin AUC was not significantly different, however, the digoxin Cmax was increased by 14%. Periodic monitoring of digoxin plasma levels, in accordance with clinical judgment and based on standard clinical practice in patients receiving this medication, is recommended during administration of lenalidomide.

Carcinogenesis, mutagenesis, impairment of fertility

Carcinogenicity: Carcinogenicity studies with lenalidomide have not been conducted.

Mutagenesis: Lenalidomide did not induce mutation in the Ames test, chromosome aberrations in cultured human peripheral blood lymphocytes, or mutation at the thymidine kinase (tk) locus of mouse lymphoma L5178Y cells. Lenalidomide did not increase morphological transformation in Syrian Hamster Embryo assay or induce micronuclei in the polychromatic erythrocytes of the bone marrow of male rats.

Fertility: A fertility and early embryonic development study in rats, with administration of lenalidomide up to 500 mg/kg (approximately 600 times the human dose of 10 mg, based on body surface area) produced no parental toxicity and no adverse effects on fertility.

Pregnancy

Pregnancy Category X: (See BOXED WARNINGS and CONTRAINDICATIONS)

Because of the structural similarity to thalidomide, a known human teratogen, and the data from an embryofetal development study showing treatment with lenalidomide produced malformations in the offspring of female monkeys who received the drug during pregnancy, REVLIMID® (lenalidomide) is contraindicated in females who are or may become pregnant and who are not using the two required types of birth control or who are not continually abstaining from reproductive heterosexual sexual intercourse. REVLIMID® (lenalidomide) should not be used by females who are pregnant or who could become pregnant while taking the drug. If pregnancy does occur during treatment, the drug should be immediately discontinued. Under these conditions, the patient should be referred to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling. Any suspected fetal exposure to REVLIMID® (lenalidomide) should be reported to the FDA via the MedWatch program at 1-800-FDA-1088 and also to Celgene Corporation at 1-888-423-5436.

Use in Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants from lenalidomide, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of 18 have not been established.

Geriatric Use

REVLIMID® (lenalidomide) has been used in del 5q MDS clinical trials in patients up to 95 years of age.

Of the 148 patients with del 5q MDS enrolled in the major study, 38% were age 65 and over, while 33% were age 75 and over. Although the overall frequency of adverse events (100%) was the same in patients over 65 years of age as in younger patients, the frequency of serious adverse events was higher in patients over 65 years of age than in younger patients (54% vs. 33%). A greater proportion of patients over 65 years of age discontinued from the clinical studies because of adverse events than the proportion of younger patients (27% vs.16%). No differences in efficacy were observed between patients over 65 years of age and younger patients.

REVLIMID® (lenalidomide) has been used in multiple myeloma (MM) clinical trials in patients up to 86 years of age.

Of the 692 MM patients enrolled in Studies 1 and 2, 45% were age 65 or over while 12% of patients were age 75 and over. The percentage of patients age 65 or over was not significantly different between the REVLIMID® (lenalidomide)/dexamethasone and placebo/dexamethasone groups. Of the 346 patients who received REVLIMID® (lenalidomide)/dexamethasone, 46% were age 65 and over. In both studies, patients > 65 years of age were more likely than patients ≤ 65 years of age to experience diarrhea, fatigue, pulmonary embolism, and syncope following use of REVLIMID® (lenalidomide). No differences in efficacy were observed between patients over 65 years of age and younger patients.

Renal Impairment

Since lenalidomide is primarily excreted unchanged by the kidney, adjustments to the starting dose of REVLIMID® (lenalidomide) are recommended to provide appropriate drug exposure in patients with moderate or severe (CLcr < 60 mL/min) renal impairment and in patients on dialysis. See DOSAGE AND ADMINISTRATION.

ADVERSE REACTIONS

Myelodysplastic Syndromes

A total of 148 patients received at least 1 dose of 10 mg lenalidomide in the del 5q MDS clinical study. At least one adverse event was reported in all of the 148 patients who were treated with the 10 mg starting dose of REVLIMID® (lenalidomide). The most frequently reported adverse events were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions. (SeePRECAUTIONS)

Thrombocytopenia (61.5%; 91/148) and neutropenia (58.8%; 87/148) were the most frequently reported adverse events observed. The next most common adverse events observed were diarrhea (48.6%; 72/148), pruritus (41.9%; 62/148), rash (35.8%; 53/148) and fatigue (31.1%; 46/148). Table 4 summarizes the adverse events that were reported in ≥ 5% of the REVLIMID® (lenalidomide) treated patients in the del 5q MDS clinical study. Table 5 summarizes the most frequently observed Grade 3 and Grade 4 adverse reactions regardless of relationship to treatment with REVLIMID® (lenalidomide). In the single-arm studies conducted, it is often not possible to distinguish adverse events that are drug-related and those that reflect the patient’s underlying disease.

Table 4: Summary of Adverse Events Reported in ≥ 5% of the REVLIMID® (lenalidomide) Treated Patients in del 5q MDS Clinical Study
NOS, not otherwise specified
[a] System organ classes and preferred terms are coded using the MedDRA dictionary. System organ classes and preferred terms are listed in descending order of frequency for the Overall column. A patient with multiple occurrences of an AE is counted only once in the AE category.
System organ class/Preferred term [a] 10 mg Overall
(N=148)
    Patients with at least one adverse event 148 (100.0)
Blood and Lymphatic System Disorders
    Thrombocytopenia 91 (61.5)
    Neutropenia 87 (58.8)
    Anemia NOS 17 (11.5)
    Leukopenia NOS 12 (8.1)
    Febrile Neutropenia 8 (5.4)
Skin and Subcutaneous Tissue Disorders
    Pruritus 62 (41.9)
    Rash NOS 53 (35.8)
    Dry Skin 21 (14.2)
    Contusion 12 (8.1)
    Night Sweats 12 (8.1)
    Sweating Increased 10 (6.8)
    Ecchymosis 8 (5.4)
    Erythema 8 (5.4)
Gastrointestinal Disorders
    Diarrhea NOS 72 (48.6)
    Constipation 35 (23.6)
    Nausea 35 (23.6)
    Abdominal Pain NOS 18 (12.2)
    Vomiting NOS 15 (10.1)
    Abdominal Pain Upper 12 (8.1)
    Dry Mouth 10 (6.8)
    Loose Stools 9 (6.1)
Respiratory, Thoracic and Mediastinal Disorders
    Nasopharyngitis 34 (23.0)
    Cough 29 (19.6)
    Dyspnea NOS 25 (16.9)
    Pharyngitis 23 (15.5)
    Epistaxis 22 (14.9)
    Dyspnea Exertional 10 (6.8)
    Rhinitis NOS 10 (6.8)
    Bronchitis NOS 9 (6.1)
General Disorders and Administration Site Conditions
    Fatigue 46 (31.1)
    Pyrexia 31 (20.9)
    Edema Peripheral 30 (20.3)
    Asthenia 22 (14.9)
    Edema NOS 15 (10.1)
    Pain NOS 10 (6.8)
    Rigors 9 (6.1)
    Chest Pain 8 (5.4)
Musculoskeletal and Connective Tissue Disorders
    Arthralgia 32 (21.6)
    Back Pain 31 (20.9)
    Muscle Cramp 27 (18.2)
    Pain in Limb 16 (10.8)
    Myalgia 13 (8.8)
    Peripheral Swelling 12 (8.1)
Nervous System Disorders
    Dizziness 29 (19.6)
    Headache 29 (19.6)
    Hypoesthesia 10 (6.8)
    Dysgeusia 9 (6.1)
    Peripheral Neuropathy NOS 8 (5.4)
Infections and Infestations
    Upper Respiratory Tract Infection NOS 22 (14.9)
    Pneumonia NOS 17 (11.5)
    Urinary Tract Infection NOS 16 (10.8)
    Sinusitis NOS 12 (8.1)
    Cellulitis 8 (5.4)
Metabolism and Nutrition Disorders
    Hypokalemia 16 (10.8)
    Anorexia 15 (10.1)
    Hypomagnesemia 9 (6.1)
Investigations
    Alanine Aminotransferase Increased 12 (8.1)
Psychiatric Disorders
    Insomnia 15 (10.1)
    Depression 8 (5.4)
Vascular Disorders
    Hypertension NOS 9 (6.1)
Renal and Urinary Disorders
    Dysuria 10 (6.8)
Cardiac Disorders
    Palpitations 8 (5.4)
Endocrine Disorders
    Acquired Hypothyroidism 10 (6.8)

Table 5: Most Frequently Observed Grade 3 and 4 Adverse Events [1] Regardless of Relationship to Study Drug Treatment
[1] Adverse events with frequency ≥1% in the 10 mg Overall group. Grade 3 and 4 are based on National Cancer Institute Common Toxicity Criteria version 2.
[2] Preferred Terms are coded using the MedDRA dictionary. A patient with multiple occurrences of an AE is counted only once in the Preferred Term category.
Preferred term [2] 10 mg
(N=148)
Patients with at least one Grade 3/4 AE 131 (88.5)
 Neutropenia 79 (53.4)
 Thrombocytopenia 74 (50.0)
 Pneumonia NOS 11 (7.4)
 Rash NOS 10 (6.8)
 Anemia NOS 9 (6.1)
 Leukopenia NOS 8 (5.4)
 Fatigue 7 (4.7)
 Dyspnea 7 (4.7)
 Back Pain 7 (4.7)
 Febrile Neutropenia 6 (4.1)
 Nausea 6 (4.1)
 Diarrhea NOS 5 (3.4)
 Pyrexia 5 (3.4)
 Sepsis 4 (2.7)
 Dizziness 4 (2.7)
 Granulocytopenia 3 (2.0)
 Chest Pain 3 (2.0)
 Pulmonary Embolism 3 (2.0)
 Respiratory Distress 3 (2.0)
 Pruritus 3 (2.0)
 Pancytopenia 3 (2.0)
 Muscle Cramp 3 (2.0)
 Respiratory Tract Infection 2 (1.4)
 Upper Respiratory Tract Infection 2 (1.4)
 Asthenia 2 (1.4)
 Multi-organ Failure 2 (1.4)
 Epistaxis 2 (1.4)
 Hypoxia 2 (1.4)
 Pleural Effusion 2 (1.4)
 Pneumonitis NOS 2 (1.4)
 Pulmonary Hypertension NOS 2 (1.4)
 Vomiting NOS 2 (1.4)
 Sweating Increased 2 (1.4)
 Arthralgia 2 (1.4)
 Pain in Limb 2 (1.4)
 Headache 2 (1.4)
 Syncope 2 (1.4)

In other clinical studies of REVLIMID® (lenalidomide) in MDS patients, the following serious adverse events (regardless of relationship to study drug treatment) not described in Table 4 or 5 were reported:

Blood and lymphatic system disorders: warm type hemolytic anemia, splenic infarction, bone marrow depression NOS, coagulopathy, hemolysis NOS, hemolytic anemia NOS, refractory anemia

Cardiac disorders: cardiac failure congestive, atrial fibrillation, angina pectoris, cardiac arrest, cardiac failure NOS, cardio-respiratory arrest, cardiomyopathy NOS, myocardial infarction, myocardial ischemia, atrial fibrillation aggravated, bradycardia NOS, cardiogenic shock, pulmonary edema NOS, supraventricular arrhythmia NOS, tachyarrhythmia, ventricular dysfunction

Ear and labyrinth disorders: vertigo

Endocrine disorders: Basedow’s disease

Gastrointestinal disorders: gastrointestinal hemorrhage NOS, colitis ischemic, intestinal perforation NOS, rectal hemorrhage, colonic polyp, diverticulitis NOS, dysphagia, gastritis NOS, gastroenteritis NOS, gastroesophageal reflux disease, obstructive inguinal hernia, irritable bowel syndrome, melena, pancreatitis due to biliary obstruction, pancreatitis NOS, perirectal abscess, small intestinal obstruction NOS, upper gastrointestinal hemorrhage

General disorders and administration site conditions: disease progression NOS, fall, gait abnormal, intermittent pyrexia, nodule, rigors, sudden death

Hepatobiliary disorders: hyperbilirubinemia, cholecystitis acute NOS, cholecystitis NOS, hepatic failure

Immune system disorders: hypersensitivity NOS

Infections and infestations: infection NOS, bacteremia, central line infection, clostridial infection NOS, ear infection NOS, Enterobacter sepsis, fungal infection NOS, herpes viral infection NOS, influenza, kidney infection NOS, Klebsiella sepsis, lobar pneumonia NOS, localized infection, oral infection, Pseudomonas infection NOS, septic shock, sinusitis acute NOS, sinusitis NOS, Staphylococcal infection, urosepsis

Injury, poisoning and procedural complications: femur fracture, transfusion reaction, cervical vertebral fracture, femoral neck fracture, fractured pelvis NOS, hip fracture, overdose NOS, post procedural hemorrhage, rib fracture, road traffic accident, spinal compression fracture

Investigations: blood creatinine increased, culture NOS negative, hemoglobin decreased, liver function tests NOS abnormal, troponin I increased

Metabolism and nutrition disorders: dehydration, gout, hypernatremia, hypoglycemia NOS

Musculoskeletal and connective tissue disorders: arthritis NOS, arthritis NOS aggravated, gouty arthritis, neck pain, chondrocalcinosis pyrophosphate

Neoplasms benign, malignant and unspecified: acute leukemia NOS, acute myeloid leukemia NOS, bronchoalveolar carcinoma, lung cancer metastatic, lymphoma NOS, prostate cancer metastatic

Nervous system disorders: cerebrovascular accident, aphasia, cerebellar infarction, cerebral infarction, depressed level of consciousness, dysarthria, migraine NOS, spinal cord compression NOS, subarachnoid hemorrhage NOS, transient ischemic attack

Psychiatric disorders: confusional state

Renal and urinary disorders: renal failure NOS, hematuria, renal failure acute, azotemia, calculus ureteric, renal mass NOS

Reproductive system and breast disorders: pelvic pain NOS

Respiratory, thoracic and mediastinal disorders: bronchitis NOS, chronic obstructive airways disease exacerbated, respiratory failure, dyspnea exacerbated, interstitial lung disease, lung infiltration NOS, wheezing

Skin and subcutaneous tissue disorders: acute febrile neutrophilic dermatosis

Vascular system disorders: deep vein thrombosis, hypotension NOS, aortic disorder, ischemia NOS, thrombophlebitis superficial, thrombosis

Multiple Myeloma

Data were evaluated from 691 patients in two studies who received at least one dose of REVLIMID® (lenalidomide)/dexamethasone (346 patients) or placebo/dexamethasone (345 patients).

In the REVLIMID® (lenalidomide)/dexamethasone treatment group, 151 patients (45%) underwent at least one dose interruption with or without a dose reduction of REVLIMID® (lenalidomide) compared to 21% in the placebo/dexamethasone treatment group. Of these patients who had one dose interruption with or without a dose reduction, 50% in the REVLIMID® (lenalidomide)/dexamethasone treatment group underwent at least one additional dose interruption with or without a dose reduction compared to 21% in the placebo/dexamethasone treatment group. Most adverse events and Grade 3/4 adverse events were more frequent in patients who received the combination of REVLIMID® (lenalidomide)/dexamethasone compared to placebo/dexamethasone.

Table 6 summarizes the number and percentage of patients with Grade 1-4 adverse events reported in ≥10% of patients in either treatment group in Studies 1 and 2.

Table 6: Number of Patients with Adverse Events Reported in at Least 10% of Patients  in Either Treatment Group in Studies 1 and 2 (Safety Population)
ª See WARNINGS
Revlimid/Dex
(N=346)
Placebo/Dex
(N=345)
System organ class/Preferred term n (%) n (%)
Subjects with at least one adverse event 346 (100.0) 344 (99.7)
Blood and Lymphatic System Disorders
 Neutropenia 96 (27.7) 16 (4.6)
 Anemia NOS 84 (24.3) 60 (17.4)
 Thrombocytopenia 59 (17.1) 34 (9.9)
Eye Disorders
 Vision Blurred 51 (14.7) 36 (10.4)
Gastrointestinal Disorders
 Constipation 134 (38.7) 64 (18.6)
 Diarrhea NOS 101 (29.2) 85 (24.6)
 Nausea 76 (22.0) 66 (19.1)
 Dyspepsia 48 (13.9) 46 (13.3)
 Vomiting NOS 35 (10.1) 28 (8.1)
General Disorders and Administration Site Conditions
 Fatigue 133 (38.4) 129 (37.4)
 Asthenia 81 (23.4) 86 (24.9)
 Pyrexia 80 (23.1) 67 (19.4)
 Edema Peripheral 73 (21.1) 65 (18.8)
Infections and Infestations
 Upper Respiratory Tract Infection NOS 47 (13.6) 43 (12.5)
 Pneumonia NOS 39 (11.3) 26 (7.5)
Investigations
 Weight Decreased 63 (18.2) 48 (13.9)
Metabolism and Nutrition Disorders
 Hyperglycemia NOS 52 (15.0) 49 (14.2)
 Anorexia 47 (13.6) 30 (8.7)
 Hypokalemia 39 (11.3) 18 (5.2)
Musculoskeletal and Connective Tissue Disorders
 Muscle Cramp 104 (30.1) 71 (20.6)
 Back Pain 53 (15.3) 49 (14.2)
 Muscle Weakness NOS 52 (15.0) 53 (15.4)
 Arthralgia 36 (10.4) 51 (14.8)
Nervous System Disorders
 Headache 74 (21.4) 74 (21.4)
 Dizziness 72 (20.8) 53 (15.4)
 Tremor 68 (19.7) 24 (7.0)
 Dysgeusia 46 (13.3) 32 (9.3)
 Paresthesia 40 (11.6) 43 (12.5)
Psychiatric Disorders
 Insomnia 111 (32.1) 128 (37.1)
Respiratory, Thoracic and Mediastinal Disorders
 Dyspnea NOS 70 (20.2) 53 (15.4)
 Cough 50 (14.5) 71 (20.6)
Skin and Subcutaneous Tissue Disorders
 Rash NOS 55 (15.9) 28 (8.1)
Vascular Disorders
 Deep Vein Thrombosisa 27 (7.8) 11 (3.2)
 Pulmonary Embolisma 11 (3.2) 3 (0.9)

Table 7 summarizes the Grade 3/4 adverse events reported in ≥2% of patients in either treatment group in Studies 1 and 2.

Table 7: Adverse Events with NCI CTC Grades 3 and 4 Reported In At Least 2% of Patients by Preferred Term and Treatment Group – (Safety Population)
ª See WARNINGS
Revlimid/Dex (N=346) Placebo/Dex (N=345)
Grade 3 Grade 4 Grade 3 Grade 4
System organ class/ Preferred term n (%) n (%) n (%) n (%)
Patients with at least one Grade 3 or 4 AE 225 (65.0) 25 (7.2) 186 (53.9) 31 (9.0)
Blood and Lymphatic System Disorders
Neutropenia 60 (17.3) 13 (3.8) 8 (2.3) 2 (0.6)
Thrombocytopenia 31 (9.0) 4 (1.2) 16 (4.6) 3 (0.9)
Anemia NOS 25 (7.2) 4 (1.2) 10 (2.9) 2 (0.6)
Leukopenia NOS 12 (3.5) 0 (0.0) 1 (0.3) 0 (0.0)
Lymphopenia 8 (2.3) 0 (0.0) 4 (1.2) 0 (0.0)
Cardiac Disorders
Atrial Fibrillation 9 (2.6) 1 (0.3) 2 (0.6) 1 (0.3)
Gastrointestinal Disorders
Diarrhea NOS 8 (2.3) 0 (0.0) 2 (0.6) 0 (0.0)
Constipation 7 (2.0) 0 (0.0) 1 (0.3) 0 (0.0)
General Disorders and Administration Site Conditions
Fatigue 20 (5.8) 1 (0.3) 13 (3.8) 0 (0.0)
Asthenia 14 (4.0) 0 (0.0) 16 (4.6) 0 (0.0)
Pyrexia 4 (1.2) 0 (0.0) 8 (2.3) 0 (0.0)
Infections and Infestations
Pneumonia NOS 18 (5.2) 4 (1.2) 15 (4.3) 3 (0.9)
Metabolism and Nutrition Disorders
Hyperglycemia NOS 22 (6.4) 4 (1.2) 19 (5.5) 7 (2.0)
Hypocalcemia 8 (2.3) 5 (1.4) 4 (1.2) 1 (0.3)
Hypokalemia 9 (2.6) 1 (0.3) 5 (1.4) 0 (0.0)
Musculoskeletal and Connective Tissue Disorders
Muscle Weakness NOS 18 (5.2) 0 (0.0) 10 (2.9) 0 (0.0)
Nervous System Disorders
Syncope 7 (2.0) 0 (0.0) 3 (0.9) 0 (0.0)
Neuropathy NOS 7 (2.0) 0 (0.0) 2 (0.6) 0 (0.0)
Psychiatric Disorders
Depression 9 (2.6) 0 (0.0) 5 (1.4) 1 (0.3)
Confusional State 6 (1.7) 0 (0.0) 8 (2.3) 0 (0.0)
Respiratory, Thoracic and Mediastinal Disorders
Dyspnea NOS 6 (1.7) 3 (0.9) 7 (2.0) 1 (0.3)
Vascular Disorders
Deep Vein Thrombosisa 23 (6.6) 1 (0.3) 9 (2.6) 1 (0.3)
Pulmonary Embolisma 2 (0.6) 9 (2.6) 1 (0.3) 2 (0.6)

Thrombotic Events (See WARNINGS)

In the pooled analysis, thrombotic or thromboembolic events, including deep vein thrombosis, pulmonary embolism, thrombosis, and intracranial venous sinus thrombosis, were reported more frequently in patients treated with REVLIMID® (lenalidomide)/dexamethasone combination. The number of patients experiencing a thrombotic event in the combination arm were 43/346 (12%) compared with those in the placebo/dexamethasone arm 14/345 (4%).

In these and other clinical studies of REVLIMID® (lenalidomide) in patients with multiple myeloma, the following serious adverse events (considered related to study drug treatment) not described in Table 7 were reported:

Blood and lymphatic system disorders: pancytopenia, anemia NOS aggravated

Cardiac disorders: cardiac failure congestive, atrial flutter, pulmonary edema

Endocrine disorders: adrenal insufficiency NOS, acquired hypothyroidism

Eye disorders: blindness

Gastrointestinal disorders: abdominal pain NOS, colitis pseudomembranous, gastritis NOS, gastrointestinal hemorrhage NOS, peptic ulcer hemorrhage, upper gastrointestinal hemorrhage

General disorders and administration site conditions: performance status decreased

Hepatobiliary disorders: hepatic failure, hepatitis toxic

Infections and infestations: bronchopneumonia NOS, cellulitis, Pneumocystis carinii pneumonia, sepsis NOS, bursitis infective NOS, cellulitis staphylococcal, Enterobacter bacteremia, Escherichia sepsis, gastrointestinal infection NOS, herpes zoster, herpes zoster ophthalmic, infection NOS, lung infection NOS, neutropenic sepsis, pneumonia bacterial NOS, pneumonia cytomegaloviral, pneumonia pneumococcal, pneumonia primary atypical, pneumonia staphylococcal, septic shock, streptococcal sepsis, subacute endocarditis, urinary tract infection NOS

Investigations: International normalized ratio increased, weight decreased, blood creatinine increased, body temperature increased, c-reactive protein increased, hemoglobin decreased, white blood cell count decreased

Metabolism and nutrition disorders: dehydration, diabetes mellitus NOS, diabetes with hyperosmolarity, diabetic ketoacidosis

Musculoskeletal and connective tissue disorders: myopathy steroid, back pain, myopathy

Nervous system disorders: dizziness, memory impairment, brain edema, cerebral infarction, cerebral ischemia, cerebrovascular accident, encephalitis NOS, intracranial hemorrhage NOS, intracranial venous sinus thrombosis NOS, leukoencephalopathy, somnolence, tremor

Psychiatric disorders: mental status changes, delirium, delusion NOS, insomnia, psychotic disorder NOS

Renal and urinary disorders: Fanconi syndrome acquired, hematuria, renal failure acute, renal failure NOS, renal tubular necrosis, urinary retention

Respiratory, thoracic and mediastinal disorders: bronchopneumopathy, hypoxia

Skin and subcutaneous tissue disorders: rash NOS, skin desquamation NOS

Vascular system disorders: phlebitis NOS, venous thrombosis NOS limb, circulatory collapse, hypertension NOS, hypotension NOS, orthostatic hypotension, peripheral ischemia

OVERDOSAGE

No cases of overdose have been reported during the clinical studies.

DOSAGE AND ADMINISTRATION

Myelodysplastic Syndromes

The recommended starting dose of REVLIMID® (lenalidomide) is 10 mg daily with water. Patients should not break, chew or open the capsules. Dosing is continued or modified based upon clinical and laboratory findings.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it would be prudent to monitor renal function.

Dose Adjustments During Treatment

Patients who are dosed initially at 10 mg and who experience thrombocytopenia should have their dosage adjusted as follows:

Platelet counts

If thrombocytopenia develops WITHIN 4 weeks of starting treatment at 10 mg daily
If baseline ≥100,000/mcL
When Platelets Recommended Course
Fall to <50,000/mcL Interrupt REVLIMID® treatment
Return to ≥50,000/mcL Resume REVLIMID® at 5 mg daily
If baseline <100,000/mcL
When Platelets Recommended Course
Fall to 50% of the baseline value Interrupt REVLIMID® treatment
If baseline ≥60,000/mcL and
returns to ≥50,000/mcL
Resume REVLIMID® at 5 mg daily
If baseline <60,000/mcL and
returns to ≥30,000/mcL
Resume REVLIMID® at 5 mg daily
If thrombocytopenia develops AFTER 4 weeks of starting treatment at 10 mg daily
When Platelets Recommended Course
<30,000/mcL or <50,000/mcL
and platelet transfusions
Interrupt REVLIMID® treatment
Return to ≥30,000/mcL
(without hemostatic failure)
Resume REVLIMID® at 5 mg daily

Patients who experience thrombocytopenia at 5 mg daily should have their dosage adjusted as follows:

If thrombocytopenia develops during treatment at 5 mg daily
When Platelets Recommended Course
<30,000/mcL or <50,000/mcL
and platelet transfusions
Interrupt REVLIMID® treatment
Return to ≥30,000/mcL
(without hemostatic failure)
Resume REVLIMID® at 5 mg every other day

Patients who are dosed initially at 10 mg and experience neutropenia should have their dosage adjusted as follows:

Neutrophil counts (ANC)+

If neutropenia develops WITHIN 4 weeks of starting treatment at 10 mg daily
If baseline ANC ≥1,000/mcL
When Neutrophils Recommended Course
Fall to <750/mcL Interrupt REVLIMID® treatment
Return to ≥1,000/mcL Resume REVLIMID® at 5 mg daily
If baseline ANC <1,000/mcL
When Neutrophils Recommended Course
Fall to <500/mcL Interrupt REVLIMID® treatment
Return to ≥500/mcL Resume REVLIMID® at 5 mg daily

If neutropenia develops AFTER 4 weeks of starting treatment at 10 mg daily
When Neutrophils Recommended Course
<500/mcL for ≥7 days or <500/mcL
associated with fever (≥38.5°C)
Interrupt REVLIMID® treatment
Return to ≥500/mcL Resume REVLIMID® at 5 mg daily

Patients who experience neutropenia at 5 mg daily should have their dosage adjusted as follows:

If neutropenia develops during treatment at 5 mg daily
+ Absolute neutrophil count
When Neutrophils Recommended Course
<500/mcL for ≥7 days or <500/mcL
associated with fever (≥38.5°C)
Interrupt REVLIMID® treatment
Return to ≥500/mcL Resume REVLIMID® at 5 mg every other day
Multiple Myeloma

The recommended starting dose of REVLIMID® (lenalidomide) is 25 mg/day with water orally administered as a single 25 mg capsule on Days 1‑21 of repeated 28-day cycles. Patients should not break, chew or open the capsules. The recommended dose of dexamethasone is 40 mg/day on Days 1‑4, 9‑12, and 17‑20 of each 28‑day cycle for the first 4 cycles of therapy and then 40 mg/day orally on Days 1‑4 every 28 days. Dosing is continued or modified based upon clinical and laboratory findings.

The effect of substituting lesser strengths of REVLIMID® (lenalidomide) to achieve a 25 mg capsule dose is unknown.

Dose Adjustments During Treatment

Dose modification guidelines, as summarized below are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicity judged to be related to lenalidomide.

Platelet counts

Thrombocytopenia
When Platelets Recommended Course
Fall to <30,000/mcL Interrupt REVLIMID® treatment, follow CBC weekly
Return to ≥30,000/mcL Restart REVLIMID® at 15 mg daily
For each subsequent drop <30,000/mcL Interrupt REVLIMID® treatment
Return to ≥30,000/mcL Resume REVLIMID® at 5 mg less than the previous dose. Do not dose below 5 mg daily

Neutrophil counts (ANC)

Neutropenia
When Neutrophils Recommended Course
Fall to <1000/mcL Interrupt REVLIMID® treatment, add G-CSF, follow CBC weekly
Return to ≥1,000/mcL and neutropenia is the only toxicity Resume REVLIMID® at 25 mg daily
Return to ≥1,000/mcL and if
other toxicity
Resume REVLIMID® at 15 mg daily
For each subsequent drop <1,000/mcL Interrupt REVLIMID® treatment
Return to ≥1,000/mcL Resume REVLIMID® at 5 mg less than the previous dose. Do not dose below 5 mg daily

Starting Dose Adjustment for Renal Impairment:

Since lenalidomide is primarily excreted unchanged by the kidney, adjustments to the starting dose of REVLIMID® (lenalidomide) are recommended to provide appropriate drug exposure in patients with moderate or severe renal impairment and in patients on dialysis. Based on a pharmacokinetic study in patients with renal impairment due to nonmalignant conditions, lenalidomide starting dose adjustment is recommended for patients with CLcr < 60 mL/min. Non-dialysis patients with creatinine clearances less than 11 mL/min, and dialysis patients with creatinine clearances less than 7 mL/min, have not been studied. The recommendations for initial starting doses for patients with multiple myeloma (MM) and myelodysplastic syndromes (MDS) are as follows:

Starting Dose Adjustment for Renal Impairment
Category Renal Function (Cockcroft-Gault CLcr) Disease
Multiple Myeloma Myelodysplastic Syndromes
Moderate Renal Impairment 30 ≤ CLcr < 60 mL/min 10 mg
Every 24 hours
5 mg
Every 24 hours
Severe Renal Impairment CLcr < 30 ml/min (not requiring dialysis) 15 mg
Every 48 hours
5 mg
Every 48 hours
End Stage Renal Disease CLcr < 30 mL/min (requiring dialysis) 5 mg
Once daily. On dialysis days the dose should be administered following dialysis
5 mg
3 times a week following each dialysis

After initiation of REVLIMID® (lenalidomide) therapy, subsequent REVLIMID® (lenalidomide) dose modification should be based on individual patient treatment tolerance, as described elsewhere in this section.

Other Grade 3/4 Toxicities

For other Grade 3/4 toxicities judged to be related to lenalidomide, hold treatment and restart at next lower dose level when toxicity has resolved to ≤ Grade 2.

HOW SUPPLIED

REVLIMID® (lenalidomide) 5 mg, 10 mg, 15 mg and 25 mg capsules will be supplied through the RevAssist® program. (See INFORMATION FOR PATIENTS)

REVLIMID® (lenalidomide) is supplied as:

White opaque capsules imprinted “REV” on one half and “5 mg” on the other half in black ink:

            5 mg bottles of 28       (NDC 59572-405-28)

            5 mg bottles of 100     (NDC 59572-405-00)

Blue/green and pale yellow opaque capsules imprinted “REV” on one half and “10 mg” on the other half in black ink:

            10 mg bottles of 28     (NDC 59572-410-28)

            10 mg bottles of 100   (NDC 59572-410-00)

Powder blue and white opaque capsules imprinted “REV” on one half and “15 mg” on the other half in black ink:

            15 mg bottles of 21     (NDC 59572-415-21)

            15 mg bottles of 100   (NDC 59572-415-00)

White opaque capsules imprinted “REV” on one half and “25 mg” on the other half in black ink:

            25 mg bottles of 21     (NDC 59572-425-21)

            25 mg bottles of 100   (NDC 59572-425-00)

Storage and Dispensing

Dispense no more than a 28-day supply.

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). [See USP Controlled Room Temperature].

雷利度胺(Revlimid)联合地塞米松显著改善骨髓瘤患者生存
2013年8月3日,赛尔基因(Celgene)8月2日公布了有关评价雷利米得(Revlimid,通用名:lenalidomide)联合地塞米松(dexamethasone)诱导疗法及雷利米得维持疗法用于高风险无症状性隐袭性多发性骨髓瘤(SMM)患者治疗的积极数据。
该项随机、多中心、开发标签III期研究数据显示,平均随访40个月后,与观察组相比,治疗组发展为有症状疾病的平均时间显着延长,3年总生存率也高于观察组,诱导期和维持期分别有79%和90%的患者产生部分反应,达到了研究的主要终点。
-------------------------------------------------------------
产地国家: 德国
原产地英文商品名:
REVLIMID 10mgX21capsules
原产地英文药品名:
LENALIDOMIDE
中文参考商品译名:
雷利米得 10毫克x21胶囊/瓶
中文参考药品译名:
雷纳利多米得
曾用名:
来那度胺
生产厂家中文参考译名:
细胞基因公司
生产厂家英文名:
Celgene
-------------------------------------------------------------
产地国家: 瑞士
原产地英文商品名:
REVLIMID 25mgX21capsules 6packs
原产地英文药品名:
LENALIDOMIDE
中文参考商品译名:
雷利米得 25毫克x21胶囊/瓶 6瓶装
中文参考药品译名:
雷纳利多米得
曾用名:
来那度胺
生产厂家中文参考译名:
细胞基因公司
生产厂家英文名:
Celgene
-------------------------------------------------------------
产地国家: 美国
原产地英文商品名:
REVLIMID 5mgX30capsules
原产地英文药品名:
LENALIDOMIDE
中文参考商品译名:
雷利米得 5毫克x30胶囊/瓶
中文参考药品译名:
雷纳利多米得
曾用名:
来那度胺
生产厂家中文参考译名:
细胞基因公司
生产厂家英文名:
Celgene
-------------------------------------------------------------
产地国家: 美国
原产地英文商品名:
REVLIMID 10mgX30capsules
原产地英文药品名:
LENALIDOMIDE
中文参考商品译名:
雷利米得 10毫克x30胶囊/瓶
中文参考药品译名:
雷纳利多米得
曾用名:
来那度胺
生产厂家中文参考译名:
细胞基因公司
生产厂家英文名:
Celgene
-------------------------------------------------------------
产地国家: 美国
原产地英文商品名:
REVLIMID 5mgX100capsules
原产地英文药品名:
LENALIDOMIDE
中文参考商品译名:
雷利米得 5毫克x100胶囊/瓶
中文参考药品译名:
雷纳利多米得
曾用名:
来那度胺
生产厂家中文参考译名:
细胞基因公司
生产厂家英文名:
Celgene
-------------------------------------------------------------
产地国家: 美国
原产地英文商品名:
REVLIMID 10mgX100capsules
原产地英文药品名:
LENALIDOMIDE
中文参考商品译名:
雷利米得 10毫克x100胶囊/瓶
中文参考药品译名:
雷纳利多米得
曾用名:
来那度胺
生产厂家中文参考译名:
细胞基因公司
生产厂家英文名:
Celgene

责任编辑:admin


相关文章
来那度胺胶囊|REVLIMID(lenalidomide capsules)
Revlimid Capsules(Lenalidomide Hydrate)来那度胺胶囊
FDA叫停Revlimid(来那度胺)治疗慢性淋巴细胞性白血病的临床试验
来那度胺胶囊|REVLIMID(lenalidomide capsules)
美国FDA核准REVLIMID(来那度胺)用于治疗复发性或难治性套细胞淋巴瘤
Revlimid获FDA批准用于特定套细胞淋巴瘤患者
来那度胺维持治疗多发性骨髓瘤
沙立度胺和来那度胺治疗骨髓纤维化的疗效对比
FDA更新来那度胺发生新恶性肿瘤风险的安全性信息
Kyprolis(carfilzomib)for Injection
 

最新文章

更多

· ZOLINZA(VORINOSTAT)C...
· Zoladex(GOSERELIN ACE...
· Zofran Injection(盐酸...
· Keytruda(Pembrolizumab...
· ODOMZO(sonidegib capsules)
· 奈拉滨注射剂(nelarabin...
· 色瑞替尼硬胶囊|Zykadia...
· 依鲁替尼硬胶囊|IMBRUVI...
· LENVIMA(Lenvatinib Me...
· XTANDI(ENZALUTAMIDE)CA...

推荐文章

更多

· ZOLINZA(VORINOSTAT)C...
· Zoladex(GOSERELIN ACE...
· Zofran Injection(盐酸...
· Keytruda(Pembrolizumab...
· ODOMZO(sonidegib capsules)
· 奈拉滨注射剂(nelarabin...
· 色瑞替尼硬胶囊|Zykadia...
· 依鲁替尼硬胶囊|IMBRUVI...
· LENVIMA(Lenvatinib Me...
· XTANDI(ENZALUTAMIDE)CA...

热点文章

更多

· ZOLINZA(VORINOSTAT)C...
· Zoladex(GOSERELIN ACE...
· Zofran Injection(盐酸...